CClinicalTrials.gg
CompletedNCT05943873Updated Jul 13, 2023

Successful Microsurgical Breast Reconstruction in Minimally Invasive Mastectomy

An observational study in Breast Reconstruction and Breast Cancer, sponsored by Chang Gung Memorial Hospital. Completed at 1 site in Taiwan. Open to female participants. Per ClinicalTrials.gov, last updated 2023-07-13.

Sponsored by Chang Gung Memorial Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
63
Sex
Female
01

Study summary

A retrospective chart review will be conducted to identify patients who received breast reconstruction surgery with DIEP flaps by a single plastic surgeon in one medical center between November 2018 and July 2022. Patients will be grouped based on how the mastectomy was performed, via minimally invasive or conventional approach. Demographic data, flap profile, vessel anastomosis and post-operative complication will be retrospectively reviewed. Data collection includes patient demographics, previous breast surgical history, breast cancer history and adjuvant therapy, surgical details and postoperative events.

02

Conditions studied

  • Breast Reconstruction
  • Breast Cancer

Keywords

  • free flap
  • breast reconstruction
  • minimally invasive mastectomy
  • nipple-sparing mastectomy
  • robotic-assisted mastectomy
  • endoscopic-assisted mastectomy
03

In context

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,064 studies on the registry; 234 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients who received nipple sparing mastectomy and breast reconstruction from November 2018 to July 2022 from a single breast reconstruction surgeon

Inclusion criteria

  • patients who received nipple sparing mastectomy and breast reconstruction from November 2018 to July 2022 from a single breast reconstruction surgeon.

Exclusion criteria

Exclusion Criteria:

  • patients failed to be examined for outcome evaluation will be excluded from the study.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
63 participants (actual)
Patient registry
No

Groups and cohorts

  • Control

    Conventional mastectomy

  • Minimally invasive

    robotic-assisted or endoscopic assisted mastectomies

06

What researchers measure

Primary outcomes

  1. Successful

    If the free flap transferred is successfully survived

    Time frame: post-operative 7 days

07

Study locations

1 site
  • ChangGungMH
    Taoyuan, 33305, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05943873
Lead sponsor
Chang Gung Memorial Hospital
Responsible party
Jung-Ju Huang (Associate Professor, Chang Gung Memorial Hospital) — Principal investigator
First posted
Jul 13, 2023
Start date
Jun 30, 2023
Primary completion
Jul 5, 2023
Completion
Jul 5, 2023
Last update
Jul 13, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion